Company Encyclopedia
View More
name
Nexgel
NXGL.US
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions.
322.01 B
NXGL.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking30/43
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-58.34%E
    • Profit Margin-24.69%E
    • Gross Margin42.37%B
  • Growth ScoreA
    • Revenue YoY73.37%A
    • Net Profit YoY18.39%B
    • Total Assets YoY9.91%B
    • Net Assets YoY11.83%B
  • Cash ScoreC
    • Cash Flow Margin-405.07%D
    • OCF YoY73.37%A
  • Operating ScoreA
    • Turnover1.05A
  • Debt ScoreC
    • Gearing Ratio52.01%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nexgel Spins Off Drug Delivery Unit into NexGelRx

    Nexgel Spins Off Drug Delivery Unit into NexGelRx

    Reuters·
    US
    NXGL
    -9.24%
    Reuters·
    US
    NXGL
    -9.24%

    Revenues Working Against NEXGEL, Inc.'s (NASDAQ:NXGL) Share Price Following 31% Dive

    NEXGEL, Inc. (NASDAQ:NXGL) shares fell 31% in a month, capping a 44% annual decline. Despite strong revenue growth, its P/S ratio of 1.3x is low compared to the industry. Analysts forecast 38% annual growth for NEXGEL, versus 130% for the industry, explaining the low P/S. Shareholders' pessimism on future revenue prospects contributes to the depressed P/S and share price. Two warning signs for NEXGEL are noted.

    Simplywall·
    US
    NXGL
    -9.24%
    Simplywall·
    US
    NXGL
    -9.24%

    Maxim Group Keeps Their Buy Rating on NexGel Inc (NXGL)

    Maxim Group analyst Naz Rahman reiterated a Buy rating on NexGel Inc, setting a price target of $6.00. The stock closed at $2.02. Rahman, who covers the Healthcare sector, has an average return of -9.3% and a 33.33% success rate. NexGel Inc has a Moderate Buy consensus with a $6.00 price target.

    Tip Ranks·
    US
    NXGL
    -9.24%
    Tip Ranks·
    US
    NXGL
    -9.24%

    Nexgel | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 2.934 M

    LB filings·
    US
    NXGL
    -9.24%
    LB filings·
    US
    NXGL
    -9.24%

    Nexgel | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 2.934 M

    LB filings·
    US
    NXGL
    -9.24%
    LB filings·
    US
    NXGL
    -9.24%
    © 2025 Longbridge｜Disclaimer